|Assessment Status||NCPE Assessment Process Complete|
|Indication||As add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1.|
|Full submission received from Applicant||19/08/2011|
|NCPE assessment completed||17/01/2012|
|NCPE assessment outcome||Reimbursement Recommended|
We consider boceprevir a highly cost-effective therapy when added to peginterferon-ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in the Irish healthcare setting.